Neuphoria Therapeutics Inc (NEUP) Fair Value & Analysis
Healthcare · US · Market cap $23.3M
Neuphoria Therapeutics Inc
NEUP · US
Fair value as of: Jul 19, 2026
From 9 valuation models · updated today
Fair value updated Jul 19, 2026, revised from $24.04 to $3.65 (−84.8%) since Jun 24, 2026. Share price −20.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $3.38 – $20.00 · fair‑value band $2.74 – $4.56 · the $3.42 price screens below the $3.65 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Neuphoria Therapeutics Inc (NEUP) currently trades at $3.42, while our model-based Fair Value estimate is $3.65, implying the stock looks roughly 6.9% fairly valued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
It earns a return on equity of -62.9%. The balance sheet holds a net cash position of $21.4M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $2.74 (bear case) to $4.56 (bull case); at $3.42, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at 7%, NEUP screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Neuphoria Therapeutics Inc reported revenue of $15.6M in FY2025 versus $928K in FY2021, a compound +102.6%/yr. Reported net income was −$370K in FY2025.
Is NEUP fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $446.83 | $261.88 | -41% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Neuphoria Therapeutics Inc (NEUP) undervalued?
What is the fair value of NEUP?
What is the quality score of NEUP?
What is the net profit margin of NEUP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Neuphoria Therapeutics Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.